Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.0
4.8
Journals
JFB
Special Issues
Nanomaterials for Drug Targeting and Drug Delivery
share announcement

Nanomaterials for Drug Targeting and Drug Delivery

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Drug Delivery".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 6070

Special Issue Editors

Dr. Chong Qiu

E-Mail Website
Guest Editor
Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
Interests: nanoparticles; nano-carriers; drug target; drug delivery
Prof. Dr. Mingzhen Zhang

E-Mail Website
Guest Editor
Institute of Medical Engineering, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an 710061, China
Interests: nanozymes; extracellular vesicles; drug delivery system; inflammation
Special Issues, Collections and Topics in MDPI journals
Dr. Nianqiu Shi

E-Mail Website
Guest Editor
Department of Pharmaceutics, School of Pharmacy, Jilin Medical College, Jilin 132013, China
Interests: nanocarriers; cell-penetrating peptides; drug delivery systems; interface penetration and delivery

Special Issue Information

Dear Colleagues,

Nanocarriers (nanoparticles, liposomes, polymers, nanoplexes and nanocapsules, etc.) have therapeutic potential to facilitate drugs’ delivery, including biological agents, small molecule drugs and nucleic acids. However, their efficiency is limited by several factors, including five consecutive processes: circulation in the blood compartments, accumulation into the target area, subsequent penetration deeply into the tissue, cellular uptake by cells, and intracellular release of drug from endosome or lysosome. For most recent nanocarriers, only < 1% could accumulate into the target tissues, cells and organelles. Hence, improving the targeting ability will inevitably improve drug efficacy and promote the clinical application of nanomedicines. The present Special Issue will focus on exploring innovative ideas or recent promising strategies to improve or regulate the targeting ability of nanocarriers for drug delivery, such as anti-cancer, bacterial infection, and vaccines, among others. Distinguished researchers are encouraged to present their studies concerning the drug fields of biomaterials, nanocarriers and controlled release, which will contribute to the smarter and more efficient design of nanodrug target delivery systems for future clinical applications.

It is our pleasure to invite all of you to submit your research to this Special Issue. Research articles, communications and review papers are welcome. To all potential authors of this Special Issue, JFB looks forward to receiving your submissions and working with you.

Dr. Chong Qiu
Prof. Dr. Mingzhen Zhang
Dr. Nianqiu Shi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • nanocarrier
  • drug delivery
  • target delivery
  • controlled release
  • biomaterials
  • nanozymes
  • extracellular vesicles

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 4057 KiB  
Article
Oral Administration of Platinum Nanoparticles with SOD/CAT Cascade Catalytic Activity to Alleviate Ulcerative Colitis
by Hao Liu, Yujie Zhang, Mingzhen Zhang, Zhaoxiang Yu and Mingxin Zhang
J. Funct. Biomater. 2023, 14(11), 548; https://doi.org/10.3390/jfb14110548 - 15 Nov 2023
Viewed by 1661
Abstract
Ulcerative colitis (UC) is a refractory chronic inflammatory disease involving the colon and rectum, falling under the category of inflammatory bowel disease (IBD). The accumulation of reactive oxygen species (ROS) in local tissues has been identified as a crucial contributor to the escalation [...] Read more.
Ulcerative colitis (UC) is a refractory chronic inflammatory disease involving the colon and rectum, falling under the category of inflammatory bowel disease (IBD). The accumulation of reactive oxygen species (ROS) in local tissues has been identified as a crucial contributor to the escalation of inflammatory responses. Therefore, eliminating ROS in the inflamed colon is a promising approach to treating UC. Nanomaterials with intrinsic enzyme-like activities (nanozymes) have shown significant therapeutic potential in UC. In this study, we found that platinum nanoparticles (Pt NPs) exhibited remarkable superoxide dismutase (SOD) and catalase (CAT) cascade catalytic activities, as well as effective hydroxyl radical (•OH) scavenging ability. The in vitro experiments showed that Pt NPs could eliminate excessive ROS to protect cells against oxidative stress. In the colitis model, oral administration of Pt NPs (loaded in chitosan/alginate hydrogel) could significantly alleviate UC, including reducing the colon length, the damaged epithelium, and the infiltration of inflammatory cells. Without appreciable systemic toxicity, Pt NPs represent a novel therapeutic approach to UC and are expected to achieve long-term inflammatory remission. Full article
(This article belongs to the Special Issue Nanomaterials for Drug Targeting and Drug Delivery)
►▼ Show Figures

Figure 1

13 pages, 7837 KiB  
Article
Hollow MIL-125 Nanoparticles Loading Doxorubicin Prodrug and 3-Methyladenine for Reversal of Tumor Multidrug Resistance
by Qingfeng Guo, Jie Li, Jing Mao, Weijun Chen, Meiyang Yang, Yang Yang, Yuming Hua and Lipeng Qiu
J. Funct. Biomater. 2023, 14(11), 546; https://doi.org/10.3390/jfb14110546 - 13 Nov 2023
Viewed by 1665
Abstract
Multidrug resistance (MDR) is a key factor in chemotherapy failure and tumor recurrence. The inhibition of drug efflux and autophagy play important roles in MDR therapy. Herein, a multifunctional delivery system (HA-MIL-125@DVMA) was prepared for synergistically reverse tumor MDR. Tumor-targeted hollow MIL-125-Ti nanoparticles [...] Read more.
Multidrug resistance (MDR) is a key factor in chemotherapy failure and tumor recurrence. The inhibition of drug efflux and autophagy play important roles in MDR therapy. Herein, a multifunctional delivery system (HA-MIL-125@DVMA) was prepared for synergistically reverse tumor MDR. Tumor-targeted hollow MIL-125-Ti nanoparticles were used to load the doxorubicin–vitamin E succinate (DV) prodrug and 3-methyladenine (3-MA) to enhance reverse MDR effects. The pH-sensitive DV can kill tumor cells and inhibit P-gp-mediated drug efflux, and 3-MA can inhibit autophagy. HA-MIL-125@DVMA had uniformly distributed particle size and high drug-load content. The nanoparticles could effectively release the drugs into tumor microenvironment due to the rapid hydrazone bond-breaking under low pH conditions, resulting in a high cumulative release rate. In in vitro cellular experiments, the accumulation of HA-MIL-125@DVMA and HA-MIL-125@DV in MCF-7/ADR cells was significantly higher than that in the control groups. Moreover, the nanoparticles significantly inhibited drug efflux in the cells, ensuring the accumulation of the drugs in cell cytoplasm and causing drug-resistant cells’ death. Importantly, HA-MIL-125@DVMA effectively inhibited tumor growth without changes in body weight in tumor-bearing mice. In summary, the combination of the acid-sensitive prodrug DV and autophagy inhibitor 3-MA in a HA-MIL-125 nanocarrier can enhance the antitumor effect and reverse tumor MDR. Full article
(This article belongs to the Special Issue Nanomaterials for Drug Targeting and Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

34 pages, 6375 KiB  
Review
Lipid–Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery
by Shweta Jain, Mudit Kumar, Pushpendra Kumar, Jyoti Verma, Jessica M. Rosenholm, Kuldeep K. Bansal and Ankur Vaidya
J. Funct. Biomater. 2023, 14(9), 437; https://doi.org/10.3390/jfb14090437 - 23 Aug 2023
Cited by 3 | Viewed by 2311
Abstract
Lipid nanoparticles (LNPs) are spherical vesicles composed of ionizable lipids that are neutral at physiological pH. Despite their benefits, unmodified LNP drug delivery systems have substantial drawbacks, including a lack of targeted selectivity, a short blood circulation period, and in vivo instability. lipid–polymer [...] Read more.
Lipid nanoparticles (LNPs) are spherical vesicles composed of ionizable lipids that are neutral at physiological pH. Despite their benefits, unmodified LNP drug delivery systems have substantial drawbacks, including a lack of targeted selectivity, a short blood circulation period, and in vivo instability. lipid–polymer hybrid nanoparticles (LPHNPs) are the next generation of nanoparticles, having the combined benefits of polymeric nanoparticles and liposomes. LPHNPs are being prepared from both natural and synthetic polymers with various techniques, including one- or two-step methods, emulsification solvent evaporation (ESE) method, and the nanoprecipitation method. Varieties of LPHNPs, including monolithic hybrid nanoparticles, core–shell nanoparticles, hollow core–shell nanoparticles, biomimetic lipid–polymer hybrid nanoparticles, and polymer-caged liposomes, have been investigated for various drug delivery applications. However, core–shell nanoparticles having a polymeric core surrounded by a highly biocompatible lipid shell are the most commonly explored LPHNPs for the treatment of various diseases. In this review, we will shed light on the composition, methods of preparation, classification, surface functionalization, release mechanism, advantages and disadvantages, patents, and clinical trials of LPHNPs, with an emphasis on core–shell-structured LPHNPs. Full article
(This article belongs to the Special Issue Nanomaterials for Drug Targeting and Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop